HHT patients exhibit at least a 50% reduction in ENG or ALK1 functional protein levels, due to their heterozygous condition for mutations in ENG (HHT1) or ALK1 (HHT2). The gene discussed is ACVRL1; the disease is hereditary hemorrhagic telangiectasia.